STAT+: Failure of Novartis Lp(a) drug raises questions about cardiovascular strategy

Coverage, in order

1. 4d ago
   
   STAT News indie study

   STAT+: Failure of Novartis Lp(a) drug raises questions about cardiovascular strategy

   CHICAGO — Lipoprotein(a), a genetic risk factor for cardiovascular disease carried by 1 in 5 people, is the target of novel therapies trying to cut down heart attacks, strokes, and deaths in those at risk. The growing field of research aimed at the particle took a hit earlier this year when…

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.